Research Article

Quality by Design assisted the Ultraviolet Spectroscopic Method Development of Donepezil hydrochloride in Bulk and Dosage form

Syeda Fatima batool¹, R. Prasanthi¹, Mamatha Tirunagari¹, Buggana Siva Jyothi^{1*}

¹ Department of Pharmaceutical Quality Assurance, Sarojini Naidu Vanita Pharmacy Maha Vidyalaya, Tarnaka, Secunderabad

Address for Correspondence

Dr. Buggana Siva Jyothi

Associate Professor,

Sarojini Naidu Vanita Pharmacy Maha Vidyalaya,

Secunderabad-500017,

ABSTRACT

Background and Objectives: A novel ultraviolet spectroscopic method was developed and validated for the drug Donepezil Hydrochloride using the latest Quality by Design software as per (ICH) guidelines. This modern scientific technology has been implemented to study the impact of independent factors affecting the resultant absorbance of the drug and the selection of the solvent.

Methods: A new method was developed by ultraviolet spectroscopy and the developed method was validated by using different validation parameters.

Results: Donepezil showed maximum absorbance at 250 nm in methanol. The concentration range for linearity was detected in the range of $60\text{-}100\mu\text{g/ml}$. The accuracy was found to be in the range of 98-100%. The chemical behavior of the drug and drug product was indicated by conducting forced degradation studies. The LOD and LOQ were determined as 2.507 $\mu\text{g/ml}$ and 7.599 $\mu\text{g/ml}$.

Conclusion: The results indicate that the QbD-assisted UV spectroscopic method for donepezil hydrochloride was simple, accurate, and precise. Therefore, it is suitable for routine analysis in quality control tests.

KEYWORDS: LOD, LOQ, ICH, Quality by design.

INTRODUCTION:

Dementia is a generalized word for various ailments such as the inability to recollect, think, and fulfill day-to-day activities. Such a condition worsens over some time. Dementia is generally noticed in elderly patients.

The following are the causes that gradually lead to dementia:

- age
- hypertension
- diabetes mellitus
- obesity
- smoking
- alcohol addiction
- being physically passive
- anxiety

At present, around 55 million people have been diagnosed with dementia, of which 33 million belong to low or average-income countries. Each year, new 10 million cases are recorded. Dementia is a result of certain diseases and head injuries. One of the common forms of dementia is Alzheimer's disease, where 60-70% of cases are reported¹. Recently, dementia has been stated as the seventh primary cause of death. It leads to intellectual inability and reliance among older patients. Management for dementia cost economically 1.3 trillion US dollars in 2019, of which 50% is accountable to immediate family or care providers who give care of around 5 hours per day. Female patients undergo higher disability-adapted life and death due to dementia, yet 70% of care hours are provided to the people living with dementia.

Quality by Design (QbD) is a systematic approach to pharmaceutical development that focuses on predefined objectives, understanding the product and process, and implementing process control based on scientific principles and quality risk management².

QbD emphasizes the value of outlining quality in various steps of production from the very beginning, instead of examining quality at the end of production. By integrating quality considerations throughout the development process, including the identification and control of potential risks, QbD aims to create high-quality pharmaceutical products consistently.

This approach aligns with principles outlined in regulatory guidelines, such as those provided by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Adhering to QbD principles can lead to more efficient development processes, reduced variability, and ultimately, improved patient outcomes.

Advantages:

Qbd offers several benefits, both from a business perspective and also in terms of scientific rigor³.

- Through QbD, companies can minimize batch failure, reducing costly setbacks and ensuring consistent product quality.
- It helps in reducing deviations, which in turn saves resources that would otherwise be spent on investigations and corrective actions.

• Mitigating the risk of regulatory compliance issues for maintaining market presence and avoiding potential fines or product recalls.

- QbD is firmly grounded in scientific principles, emphasizing a methodical and risk-based outlook to product development.
- By integrating scientific knowledge and understanding into the development process, QbD enables informed decision-making at every stage.

Donepezil hydrochloride⁴ is a hydrochloride salt that belongs to the class of acetylcholinesterase inhibitors and is effectively used in the treatment of dementia. It acts through the inhibition process of acetylcholinesterase which leads to obstruction of hydrolysis of the acetylcholine neurotransmitter. It improves the overall neurological function in Alzheimer's disease and also reduces the sedation in cancer patients due to the result of opioid treatment. It is a USFDA-approved drug for the therapy of mild to moderate dementia in Alzheimer's disease. It is currently being marketed under the brand name Aricept. The IUPAC name of donepezil hydrochloride is 2-[(1-benzylpiperidin-4-yl) methyl]-5,6-dimethoxy-2,3-dihydroinden-1-one; hydrochloride.

Donepezil hydrochloride **Figure 1** is a hydrochloride salt of piperidine derivative which possesses a neurocognitive enhancing activity. In this work, authors tried to develop a new QBD-assisted method development and validate all the parameters of Donepezil hydrochloride by UV spectrophotometry.

Figure 1: Structure of Donepezil hydrochloride

MATERIALS & METHODS:

Instruments:

The UV/Vis spectrophotometer employed in the validation process of donepezil was a UV3200 model from Lab India. Other instruments used were Weighing balance, Hot air oven, UV chamber, Rotary shaker, FTIR

Chemicals and reagents:

The API Donepezil hydrochloride was collected from Dr. Reddy's Laboratories.

Selection of Solvent with QBD software:

To select the appropriate solvent for dissolving donepezil hydrochloride, the QbD software was used. Through this software, numerous trials were conducted with different kinds of solvents like 0.1 N HCL, 0.1N NaOH, Acetonitrile, and methanol and tested for the

maximum absorbance of donepezil hydrochloride. The maximum absorbance (λ max) was found to be at 250 nm in methanol. Therefore, methanol was selected as the solvent for the donepezil hydrochloride validation process.

Impact of independent variables on λ max:

The QbD software- Design Expert 13 was applied to check the impact of independent variables on dependent variables. Sonication time, ratio of solvent, and scan speed were selected as independent variables. The impact of these variables on absorbance (dependent variable) was checked and tabulated in **TABLE 1**

| | Factor 1 | Factor 2 | Factor 3 |
|-----|--------------------|----------------|---------------|
| Run | A: Sonication(min) | B: Solvent (%) | C: Scan Speed |
| 1 | 15 | 95 | Fast |
| 2 | 15 | 95 | Fast |
| 3 | 10 | 100 | Fast |
| 4 | 15 | 90 | Slow |
| 5 | 15 | 90 | Medium |
| 6 | 10 | 90 | Fast |
| 7 | 20 | 95 | Slow |
| 8 | 10 | 95 | Slow |
| 9 | 15 | 100 | Medium |
| 10 | 10 | 95 | Medium |
| 11 | 15 | 100 | Slow |
| 12 | 20 | 100 | Fast |
| 13 | 20 | 95 | Medium |
| 14 | 20 | 90 | Fast |
| 15 | 15 | 95 | Fast |
| 16 | 20 | 95 | Slow |

TABLE-1: Independent variables

Preparation of Standard Stock Solution:

A stock solution of donepezil hydrochloride ⁵ 1mg/ml solution was prepared.

Preparation of working standard solutions:

From the above stock solution, a series of dilutions of concentrations of 60,70,80,90,100 $\mu g/ml$ were prepared as working standard solutions.

Preparation of test solution:

The average weight of 10 powdered tablets was taken and the weight equivalent to 1mg powder was measured and a stock solution of the drug product was prepared ⁶. From this solution, serial dilutions were made.

Determination of absorbance maxima (λ max): A 10 μ g/ml was used to measure the absorbance of the donepezil hydrochloride solution. The solution was examined in the range of 200-400 nm. λ max of donepezil hydrochloride was noted at 250 nm.

Using the UV spectroscopy method, donepezil hydrochloride is further validated by the QbD process.

METHOD VALIDATION 7:

The following parameters were validated for donepezil hydrochloride.

Linearity:

An array of solutions was prepared at concentrations of $60\text{-}100~\mu\text{g/ml}$. These sample solutions were scanned for absorbance at 250 nm. Beer-Lambert's law compliance was checked by plotting a graph between concentration vs. absorbance. Linearity complied with Beer's law and the values were in optimal range.

Precision:

Intra-day and Inter-day studies were conducted on one particular concentration solution from a linearity range and the absorbance of that particular concentration was measured six times a day at different time intervals and also Inter-day absorbance was measured and the %RSD was calculated.

Accuracy: Three percentage levels of concentration were selected i.e. 50%, 100%, and 150% for accuracy determination ⁸. All the sample solutions were spiked at 70μg/ml concentration with drug product and the three replicates of concentrations of 35,70,105 ppm at each percentage were prepared and scanned in the UV spectrophotometer at 250 nm to measure the absorbance and calculated the % recovery.

%Recovery =
$A0$
mount found \times 100
Amount taken

Robustness:

This test was performed by evaluating values at two different wavelengths (250 \pm 1). The absorbance was recorded and %RSD was established.

Ruggedness:

The sample solutions were prepared and checked for various analytical parameters like different analysts and different laboratory conditions.

Forced Degradation Studies:

These are a type of stability testing studies that describe the degradation rate of the drug when it undergoes certain stressful conditions that might occur during storage and after administration to the body⁹. The following are the several types of forced degradation studies.

Acid Degradation:

A solution of 6 ml of 10 ppm drug solution and 10 ml of 0.1N HCl was taken in a 50 ml graded volumetric flask and kept in a rotary shaker for 6 hours. To neutralize the solution 0.1N NaOH is used and volume is made up with methanol.

Base Degradation:

A solution of 6 ml of 10 ppm drug solution and 10 ml of 0.1 N NaOH was taken into a 50 ml graded volumetric flask and kept in a rotary shaker for 6 hours. To neutralize the solution 0.1N HCl is used and the volume is made up with methanol.

Oxidative Degradation:

A 50 ml volumetric flask is taken and 6 ml of 10 ppm drug solution and 10 ml of 3% H₂O₂ is added and kept in a rotary shaker for 6-7 hours and made up to the mark with methanol.

Thermal Degradation:

In this test, a hot air oven is employed. In this study,5 mg of donepezil hydrochloride was taken in a petri dish and placed in a hot air oven for 6 hours. After cooling, the drug was taken into a 50 ml volumetric flask and the solution was made up of methanol.

UV Degradation: In this study, 5 mg of API was taken in a petri dish and placed in a UV chamber at a wavelength of 256 nm for around 6 hours. Later this Petri dish was removed and the drug was taken into a 50 ml marked volumetric flask and the volume was formulated with methanol.

Limit of detection and limit of quantification:

The parameters limit of detection and limit of quantification were determined using one of the three methods i.e., Residual SD of the regression line¹⁰. The following equations are as per ICH (International Conference on Harmonization) guidelines.

LOD=
$$3.3 \times \sigma/S$$

LOD=
$$10 \times \sigma/S$$

Where σ = the standard deviation of the response; S = the slope of the regression line.

RESULTS:

Linearity of Donepezil Hydrochloride:

The linearity of the drug was taken for the serial concentrations of $60,70,80,90,100 \,\mu g/ml$ and absorbance was noted at λ max 250 nm with the help of a UV3200 model -Lab India spectrophotometer. The absorbance was stated at 250 nm correlating to each concentration and was recorded (**Table 2**). The calibration curve was marked with absorbance on the Y-axis and concentration on the X-axis (**Figure 2**). The experiment was performed in triplicate and analyzed as \pm SD of Donepezil hydrochloride.

| S. No | CONCENTRATION(µg/ml) | ABSORBANCE |
|-------|----------------------|------------|
| 1 | 60 | 0.5531 |
| 2 | 70 | 0.6606 |
| 3 | 80 | 0.7567 |
| 4 | 90 | 0.8413 |
| 5 | 100 | 0.9354 |

Table 2: Linearity study for Donepezil Hydrochloride




Figure 2: Calibration curve of Donepezil Hydrochloride

Precision:

For this parameter, the method was tested by using a tablet stock solution. Intraday precision was calculated by experimenting six times on the same day and on separate days for Interday precision studies. The obtained results are as below (Table 3)

| S.no | Intra-day precision Absorbance | Inter-day precision Absorbance |
|---------|--------------------------------------|-----------------------------------|
| 1 | 0.9251 | 0.8316 |
| 2 | 0.9259 | 0.8317 |
| 3 | 0.9261 | 0.8320 |
| 4 | 0.9268 | 0.8304 |
| 5 | 0.9271 | 0.8314 |
| 6 | 0.9273 | 0.8322 |
| Average | 0.926383 | 0.83155 |
| SD | 0.000835 | 0.000632 |
| %RSD | 0.90164 | 0.075962 |

TABLE-3: Precision study for Donepezil Hydrochloride

Accuracy:

The accuracy of an analytical method indicates the similarity between the recorded value and reference value. The recovery studies were conducted by another calibrated method. The results recorded were found to be sufficiently good and are as follows. (**Table 4**)

| Conce ntratio n | Drug Substance | Drug product | %recover y | Mean Recovery | % RSD |
|-----------------------|-------------------|-----------------|---------------|------------------|--------|
| 50% | 35ppm | 70ppm | 99.8% | | |
| 50% | 35ppm | 70ppm | 99.02% | 98.95 | 0.8859 |
| 50% | 35ppm | 70ppm | 98.05% | | |
| 100% | 70ppm | 70ppm | 100.0% | | |
| 100% | 70ppm | 70ppm | 100.9% | 100.93 | 0.9416 |
| 100% | 70ppm | 70ppm | 101.9% | | |
| 150% | 105ppm | 70ppm | 99.4% | | |
| 150% | 105ppm | 70ppm | 98.5% | 98.9 | 0.4557 |
| 150% | 105ppm | 70ppm | 98.9% | | |

TABLE-4: Accuracy study for Donepezil Hydrochloride

Robustness:

The Robustness of the method was calculated by modifying the wavelength ± 1 nm from 249nm and 251nm (AML) and the results were satisfactory (**Table 5**)

| S.No | Absorbance At | Absorbance At |
|---------|---------------|---------------|
| | 249nm | 251nm |
| 1 | 0.8528 | 1.0216 |
| 2 | 0.8480 | 1.0226 |
| 3 | 0.8491 | 1.0260 |
| 4 | 0.8405 | 1.0223 |
| 5 | 0.8489 | 1.0242 |
| 6 | 0.8493 | 1.0239 |
| Average | 0.8481 | 1.02344 |
| SD | 0.004073 | 0.00159 |
| %RSD | 0.480231 | 0.15538 |

TABLE-5: Robustness study for Donepezil Hydrochlorid

Ruggedness:

Ruggedness was achieved by examining the of Donepezil hydrochloride sample with different instruments and analysts. The results were determined in terms of %RSD (**Table 6**).

| Instrument nan | ne: Shimadzu | Instrument name: Lab India | | |
|----------------|--------------|----------------------------|------------|------------|
| Day 1: | | Day 2: | | |
| | analyst-1 | analyst-2 | analyst-3 | analyst-4 |
| Concentration | Absorbance | Absorbance | Absorbance | Absorbance |
| 70PPM | 0.8309 | 0.8201 | 0.709 | 0.671 |
| 70PPM | 0.8307 | 0.8234 | 0.708 | 0.675 |
| 70PPM | 0.8311 | 0.8241 | 0.703 | 0.660 |
| 70PPM | 0.8316 | 0.8301 | 0.720 | 0.657 |

| 70PPM | 0.8322 | 0.8160 | 0.701 | 0.653 |
|---------|----------|----------|----------|-----------|
| 70PPM | 0.8311 | 0.8151 | 0.707 | 0.652 |
| Average | 0.831267 | 0.821467 | 0.708 | 0.6613333 |
| SD | 0.000547 | 0.005612 | 0.006633 | 0.009564 |
| %RSD | 0.065744 | 0.683213 | 0.9369 | 1.446142 |

TABLE-6: Ruggedness for Donepezil Hydrochloride

Limit of Detection and Limit of Quantification

The LOD & LOQ were evaluated by the equations LOD = $3.3 \times \sigma/s$ and LOQ = $10 \times \sigma/s$, where σ is the standard deviation of the response areas of the drugs, taken as a measure of noise, and S is the slope of the corresponding calibration plot. The Limit of detection and Limit of quantification were recorded and are found within the limits (**Table 7**).

| Parameter | Type of method | Observation |
|-----------|--------------------------------|-------------|
| LOD | Residual SD of regression line | 2.507µg/ml |
| LOQ | Residual SD of regression line | 7.599µg/ml |

TABLE-7: LOD & LOQ

Degradation studies:

Forced degradation studies were carried out for both drug substance and drug product and results were reported as follows (**Table 8**, **Figure 3**)

| Nature of stress | %Degradation of | %Degradation of |
|-----------------------|-----------------|-----------------|
| | API | drug product |
| Acid degradation | 93.84 | 95.80 |
| Base degradation | 90.6 | 73.34 |
| Oxidation degradation | 83.73 | 94.22 |
| Thermal degradation | 93.38 | 92.54 |
| Light degradation | 88.12 | 93.09 |

TABLE 8: Forced Degradation Studies




Figure 3: Graphical Representation of Forced Degradation Studies

Optimization formulation by the Custom model method by using Design Expert Software 13

The Method was optimized by taking three independent variables such as sonication time, the ratio of solvent, and scan speed, and their effect on the dependent variable which is the absorbance of the sample. The custom model method was used to optimize the method because this method only helps to determine both Qualitative and Quantitative factors simultaneously. In our method, we selected both quantitative factors (sonication time, ratio of solvent) and Qualitative factors (Scan speed) and their impact on absorbance (response). The results shown below indicate the sample showed good absorbance with sonication time between 15-20min, the ratio of solvent between 95-100%, and scan speed medium (**Table 9**). In the below overlay plot, the optimized readings of the independent variables are shown (**Figure 4,5,6**) which are Scan speed –medium, Sonication time- 18 min, and Solvent –97 %. The designed model is desirable as the value we got 1 which is the maximum value (normal range is 0.6-1)

| | factor 1 | factor 2 | factor 3 | response |
|-----|------------|----------|----------|------------|
| run | Sonication | Solvent | Scan | Absorbance |
| | (min) | (%) | Speed | |
| 1 | 15 | 95 | Fast | 1.213 |
| 2 | 15 | 95 | Fast | 1.211 |
| 3 | 10 | 100 | Fast | 1.542 |
| 4 | 15 | 90 | Slow | 1.411 |
| 5 | 15 | 90 | Medium | 1.409 |
| 6 | 10 | 90 | Fast | 1.642 |
| 7 | 20 | 95 | Slow | 1.153 |
| 8 | 10 | 95 | Slow | 1.577 |
| 9 | 15 | 100 | Medium | 0.914 |
| 10 | 10 | 95 | Medium | 1.573 |
| 11 | 15 | 100 | Slow | 0.91 |
| 12 | 20 | 100 | Fast | 0.852 |

| 13 | 20 | 95 | Medium | 1.157 |
|----|----|----|--------|-------|
| 14 | 20 | 90 | Fast | 1.333 |
| 15 | 15 | 95 | Fast | 1.243 |
| 16 | 20 | 95 | Slow | 1.151 |

TABLE-9: Effect of independent variables on absorbance




Figure 4: Overlay plot to determine sonication time and ratio of solvent




Figure 5: Effect of independent variables on dependent variables




Figure 6: Plot to determine the desirability of the method

Anova results for the designed model:

The ANOVA results of the designed model are as follows (**Table 10**). The < 0.0001 (which is lower than 0.0005) P value specifies the designed model is significant. Lack of fit F-value is not significant indicating that there is not much variability between the three repeated center points hence the designed model is significant. The F-value is 153.06 means the model is significant. The presence of square terms in ANOVA results indicates the model is a reduced quadratic model which indicates the 3-D surface plot is a curve (**Figure 7**). In the below 3-D plot, as the sonication time increases initially the absorbance decreases and then increases and is represented in the form of a curve. Apart from this the FIT Statistics (**Table 11**) show the Adequate precision is 65.6567 which is >4 hence the model is significant. The difference between adjusted R² 0.9892 and predicted R² 0.8855 which is <0.2 indicates the model is significant.

| source | sum of | df | mean | f-value | P-value | |
|----------------|---------|----|--------|---------|----------|-------------|
| | squares | | Square | | | |
| model | 0.9617 | 9 | 0.1019 | 153.06 | < 0.0001 | |
| A- | 0.4317 | 1 | 0.4317 | 648.72 | < 0.0001 | |
| Sonicatio | | | | | | |
| n | | | | | | |
| B-Solvent | 0.3109 | 1 | 0.3109 | 467.16 | < 0.0001 | |
| C-Scan | 0.0012 | 2 | 0.0006 | 0.9304 | 0.4447 | Significant |
| speed | | | | | | |
| AB | 0.0363 | 1 | 0.0363 | 54.54 | 0.0003 | |
| BC | 0.0215 | 2 | 0.0108 | 16.18 | 0.0038 | |
| A^2 | 0.1024 | 1 | 0.1024 | 153.89 | < 0.0001 | |
| \mathbf{B}^2 | 0.0072 | 1 | 0.0072 | 10.86 | 0.0165 | |
| Residual | 0.0040 | 6 | 0.0007 | | | |
| Lack of fit | 0.0033 | 3 | 0.0011 | 5.19 | 0.1046 | Not |
| Pure error | 0.0006 | 3 | 0.0002 | | | significant |
| Cor Total | 0.9207 | 15 | | | | |

Table 10: ANOVA results for Absorbance

Fit Statistics:

| standard deviation | mean | C.V% | R ² | adjusted R ² | predicted R ² | adequate precision |
|-----------------------|------|------|----------------|----------------------------|-----------------------------|--------------------|
| 0.0258 | 1.27 | 2.03 | 0.9957 | 0.9892 | 0.8855 | 36.6567 |

Table 11: FIT Statistics




Figure 7: 3D surface plot for ANOVA results

DISCUSSION:

We developed and validated the QbD-assisted UV Spectrophotometric method for Donepezil Hydrochloride in both Bulk and Dosage formulation. Quality by design software method was used for the selection of solvent and also to study the effect of independent factors on the dependent factor which is absorbance has made this validation process more accurate and reliable. Based on the results the accurate percentage of solvent required for the method development was 97% of methanol with 18min sonication time required to solubilize the drug in the solvent. Based on these results we developed a method and validated the developed method where we got results within the limits. Apart from this we also carried out forced degradation studies in both bulk and dosage form. This advanced method was observed as robust and rugged in nature and was successfully used for the estimation of Donepezil Hydrochloride.

CONCLUSION:

We developed and validated the QbD-assisted UV Spectrophotometric method for Donepezil Hydrochloride in both Bulk and Dosage formulation. The developed method was successfully applied for the estimation of drug content in Donepezil Hydrochloride 10mg Tablets I.P. Percentage assay of Aricept®—ODT tablet was found to be 99.94. Quality by design software method was used for the selection of solvent and also to study the effect of independent factors on the dependent factor which is absorbance has made this validation process more accurate and reliable. After observing the validated parameters: accuracy, precision, LOD & LOQ were within limits. A lesser LOQ value specifies that the preferred method would be appropriate for analysing the samples containing even lower quantities of drugs. This advanced method was observed as robust and rugged in nature and was successfully used for the estimation of Donepezil Hydrochloride. Forced degradation studies of drugs and drug products were also studied. The results indicate that the QbD-assisted UV spectroscopic method for donepezil hydrochloride was simple, accurate, and precise. Therefore, it is suitable for routine analysis in quality control tests.

CONFLICT OF INTEREST: The author(s) declare(s) that they have no conflict of interest.

AUTHOR'S CONTRIBUTIONS:

The first author has contributed by doing a literature survey, performing the bench work, and writing the manuscript.

The corresponding author has contributed by editing the manuscript and providing guidance throughout the project.

Other authors have contributed by working on the QbD process and reviewing the manuscript.

REFERENCES:

- 1. Anders Gustavsson et al., Global estimates on the number of persons across the Alzheimer's disease continuum, Alzheimer's & Dementia, 2023, 19(2), 658-670.
- 2. Lan Zhang, Shirui Mao. Application of quality by design in the current drug development, Asian Journal of Pharmaceutical Sciences, 2017, 12(1), 1-8.
- 3. Frederick G Vogt, Alireza S. Kord, Development of Quality-By-Design Analytical Methods, Journal of Pharmaceutical Sciences, 2011,100(03),797-812.
- 4. Yousif A. Asiri & Gamal A.E. Mostafa. Donepezil, Profiles of Drug Substances, Excipients, and Related Methodology, 2010,10;118-148.
- 5. Sivagami B, Chandrasekar R, Pavan Kumar V, Sreesha R and Reddy Padmaja B., An analytical review on method development and validation of drugs used for Alzheimer's disease, International Journal of Advances in Pharmaceutical Analysis; 2017, 07(04),32-37.
- 6. Arun Shirwaikar, Sarala Devi, Rajagopal. P. L, Kiron. S.S & Sreejith. K.R. Development and Validation of Analytical Method for Determination of Donepezil Hydrochloride in Pure and Dosage Forms, Asian Journal of Pharmaceutical and Clinical Research;2014,07,149-153.

7. Pallavi Turukmane, Charushila Bhangale.A Comprehensive Review on Analytical Methods for the Simultaneous Estimation of Donepezil and Memantine In Combined Dosage Form, International Journal in Pharmaceutical Sciences;2023,1(5), 257-267.

- 8. Mohd Yasir, UVS Sara., development of UV spectrophotometric method for the analysis of acetyl cholinesterase inhibitor, International Journal of Pharmacy and Pharmaceutical Sciences, 2014, 6(9), 128-131.
- 9. Norio Yasui-Furukori, Rie Furuya, Takenori Takahata, Tomonori Tateishi. Determination of donepezil, an acetylcholinesterase inhibitor, in human plasma by high-performance liquid chromatography with ultraviolet absorbance detection, Journal of Chromatography B, 2002,768, 261–265.
- 10. T. Senthil Kumar, P. Solairaj, A. Thanga Thirupathi. Analytical Method Development and Validation of Donepezil Hydrochloride Tablets by RP-HPLC, International Journal of Pharmacy and Pharmaceutical Sciences, 2011, 3(3), 62-65.